Clinical Trials

39 enrolled

Prostatic Neoplasms

NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

39 enrolled

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

862 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT07198633 2025-09-30

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Phase 1/2 Not yet recruiting

212 enrolled

Phase 1/2 Active not recruiting

Advanced Prostate Cancer

NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

44 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05057013 2025-08-11

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

81 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT07104110 2025-08-05

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Phase 1/2 Not yet recruiting

50 enrolled

Prostatic Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

173 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

275 enrolled

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04145375 2025-03-19

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Phase 1/2 Enrolling by invitation

40 enrolled

Prostatic Neoplasms

NCT05075577 2025-02-28

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Phase 1/2 Terminated

77 enrolled

Prostatic Neoplasms

NCT03177187 2024-09-26

ACE

Phase 1/2 Terminated

30 enrolled

Metastatic Castration Resistant Prostate Cancer

NCT02555189 2024-05-13

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

46 enrolled

Prostatic Neoplasms

NCT02935205 2023-11-29

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Phase 1/2 Unknown

38 enrolled

Prostatic Neoplasms

NCT03437941 2023-05-06

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

39 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03709550 2022-10-05

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Withdrawn

Prostatic Neoplasms

NCT05191017 2022-08-05

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Phase 1/2 Withdrawn

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02012296 2022-07-13

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

88 enrolled 14 charts

Prostatic Neoplasms

NCT02711956 2021-11-30

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

75 enrolled 31 charts

Prostatic Neoplasms

NCT02607228 2020-12-08

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Phase 1/2 Terminated

31 enrolled 22 charts